Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
RESEARCH TOOLSreports
Holding KNSA?
Track your performance easily
KNSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.12 - $27.92
Previous Close$25.27
Volume424.00K
Average Volume (3M)472.69K
Market Cap
$1.80B
Enterprise Value$1.59B
Total Cash (Recent Filing)$218.76M
Total Debt (Recent Filing)$11.40M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Oct 28, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding71,243,712
10 Day Avg. Volume317,571
30 Day Avg. Volume472,685
Standard Deviation0.17
R-Squared0.00960
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.14
Price to Sales (P/S)5.34
Price to Cash Flow (P/CF)87.50
P/FCF Ratio87.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.08
Enterprise Value/Gross Profit6.73
Enterprise Value/Ebitda2.46K
Forecast
1Y Price Target
$35.00Price Target Upside33.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Kiniksa Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug DevelopmentClinical validation for CD40 as a target has been reinforced, providing a strong basis for future studies in conditions such as Sjogren's Syndrome.
Financial Health And Company OutlookWith a healthy capital position and a cash runway extending into at least 2027, the company exhibits solid financial stability, underpinning its capacity for sustained growth and development.
Product Adoption And Sales MomentumArcalyst is gaining traction as a preventive and maintenance treatment, with an increasing number of repeated prescribers signaling its growing acceptance in the medical community.
Bears Say
Clinical Trial ResultsKPL-404 phase 2 trial results mixed.
Drug Development UncertaintyPhase 2 abiprubart proof-of-concept data show signal but path forward contingent upon more data.
Drug EfficacyCohort 4 in rheumatoid arthritis just missed statistical significance on the primary endpoint of change from baseline in DAS28-CRP at Week 12.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $14.12 and its highest was $27.92 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Currently, no data Available
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Oct 28, 2024 which is in 38 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 40,608,970 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Among the largest hedge funds holding Kiniksa Pharmaceuticals’s share is Fairmount Funds Management Llc. It holds Kiniksa Pharmaceuticals’s shares valued at 60M.
---
Kiniksa Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (33.33% Upside)
$35.00 (33.33% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 21.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.73%
12-Months-Change
Fundamentals
Return on Equity
-2.42%
Trailing 12-Months
Asset Growth
12.00%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
---
KNSA Company Deck
---
KNSA Earnings Call
Q1 2024
0:00 / 0:00
---
KNSA Stock 12 Month Forecast
Average Price Target
$35.00
▲(33.33% Upside)
Technical Analysis
Best Analysts Covering KNSA
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+31.79%
assigned a buy rating 5 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +31.79% per trade.
---